You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
An Alberta-based research group plans to launch a blood test that could improve the specificity of prostate cancer diagnosis and reduce the number of biopsies.
Market growth is providing opportunities for emerging diagnostic companies and a range of options for clinicians, included PCR and protein tests.
The company expects to use its centrifugal microfluidic platform to launch a dengue assay early in 2018 and a Zika-dengue assay later in 2018.
Biocartis and MRCT are planning to develop a range of molecular diagnostic assays for Biocartis' fully automated Idylla platform.
The assay employs nanoplasmonics and protein-signal multiplexing in taking aim at early clinical detection of pancreatic ductal adenocarcinoma.
The researchers said that they are developing a fiber probe that could generate a Bessel beam that could be inserted into arteries to obtain internal images.
MultiGen said its test identified and confirmed the BRAF p.V600E mutation with a thousandfold increase in sensitivity compared to competing PCR-based and NGS methods.
Quanterix's Simoa single-molecule detection method combined with high-affinity antibodies detected minute levels of problematic interferon alpha proteins, a study said.
They have also developed an exosome-based test for high volume laboratory applications that was recently licensed by Exosome Diagnostics.
Venture accelerator Dreamit has selected the firm to participate in a business bootcamp that may fast-track the startup's go-to-market plan.